Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Current Liabilities: 2014-2024

Historic Total Current Liabilities for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $26.1 million.

  • KalVista Pharmaceuticals' Total Current Liabilities was N/A to $26.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $26.1 million, marking a year-over-year change of. This contributed to the annual value of $22.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Total Current Liabilities of $26.1 million as of Q4 2024, which was up 17.82% from $22.2 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' Total Current Liabilities' 5-year high stood at $26.1 million during Q4 2024, with a 5-year trough of $6.5 million in Q1 2021.
  • Its 2-year average for Total Current Liabilities is $20.6 million, with a median of $22.2 million in 2024.
  • In the last 5 years, KalVista Pharmaceuticals' Total Current Liabilities tumbled by 57.23% in 2020 and then surged by 58.58% in 2024.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Total Current Liabilities stood at $9.5 million in 2020, then plummeted by 33.23% to $6.5 million in 2021, then reached $17.8 million in 2023, then rose by 24.86% to $26.1 million in 2024.
  • Its last three reported values are $26.1 million in Q4 2024, $22.2 million for Q4 2024, and $22.4 million during Q3 2024.